Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MedicBK CDSS for Neoadjuvant Breast Cancer
NCT04802941Unknown
- Sponsor
- Pirogov National Medical and Surgical Center
- Start
- Mar 2021
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Pirogov National Medical and Surgical Center. Primary endpoint: Pathological Complete Response at 30 weeks. Status: unknown.
Beyond the preview
Go deeper on NCT04802941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04802941.